Company Overview and News
After yesterday´s positive price action the ROTY model account is firmly in the green for the month of January (so far). (181-2)
ROTY had a solid December and January appears to be starting on a strong note as well. (107-1)
Despite recent doom and gloom talk that came as a result of the pullback in fall, it has still been a decent year. (482-1)
The company is engaged in two phase 2 clinical trials evaluating safety and efficacy of lead candidate Aramchol in NASH. (80-0)
Performance of the ROTY model account has suffered lately due to both continued weakness in the biotech sector as well as a couple losers that we cut recently. (15-0)
Good day and welcome to the Galmed Pharmaceuticals Third Quarter 2017 Earnings Call. Today's call is being recorded.
Good morning and welcome to the Galmed Pharmaceuticals Second Quarter 2017 Earnings Call. Before we begin, please note that we will be making certain forward-looking statements on today’s call, including those regarding financial results, statements and forecasts regarding anticipated timelines and expectations with respect to our regulatory and clinical development programs as well as other statements that relate to future events.
Biotech fell some one percent last week as the sector continues to consolidate June large gains and there remains a dearth of new M&A activity.
Data presented at EASL continued to indicate the significant potential of Aramchol in the NASH setting.
Galmed Pharmaceuticals Ltd. (GLMD - Free Report) was a big mover last session, as the company saw its shares jump nearly 16% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend for the company as the stock is now trading above the volatile price range of $6.02 to $6.85 in the past one-month time frame.
LONDON, July 5, 2017 /PRNewswire/ -- Will novel therapies revolutionise the treatment of NASH? No drug therapies have been approved for patients with nonalcoholic steatohepatitis (NASH) but how is this set to change within the next five years? Allergan/Tobira's cenicriviroc and Gilead's selonsertib have entered the Phase III pipeline but how do they compare with other agents, Intercept's obeticholic acid and Genfit's elafibranor. (0-1)
Good morning and welcome to the Galmed Pharmaceuticals First Quarter 2017 Earnings Call. Before we begin, please note that Galmed will be making certain forward-looking statements on today’s call, including those regarding financial results, statements, forecasts regarding anticipated timelines and expectations with respect to regulatory and clinical development programs as well as other statements that relate to future events.
Large drugmakers with piles of cash are on the hunt for promising medicines being developed by small companies to treat NASH, a progressive fatty liver disease poised to become the leading cause of liver transplants by 2020. (0-1)
Welcome to another edition of "3 Things in Biotech You Should Learn Today," a digest covering recent material events in the world of pharmaceuticals and biotechnology. Today, we're fidgeting between some coverage in oncology and liver disease, and it's all good news! I dig it.
2017-12-11 - Wilton
2017-12-11 - Wilton
2017-12-03 - Wilton
2017-11-27 - Wilton